The Lancet: “COVID-19 vaccine development pipeline gears up.” June 6, 2020.
News releases, Moderna: “Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus,” “Moderna Announced Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus.”
News release, AstraZeneca: “AstraZeneca takes next steps towards broad and equitable access to Oxford University’s COVID-19 vaccine.”
News release, Pfizer and BioNTech: “Pfizer and BioNtech Dose First Participants in the U.S. As Part of Global Covid-19 MRNA Vaccine Development Program.”
News release, Inovio: “Inovio Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June.”
The Lancet: “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.”
Clinical Trials.gov: “A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVIDd-19 (Adenovirus Vector) (CTII-nCoV). “
Yahoo: “5 Promising COVID-19 Vaccines Now Selected for Trump’s Operation Warp Speed,” June 3, 2020.
News release, Johnson & Johnson: “Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July.”
Wall Street Journal: “Coronavirus Vaccine Candidates’ Pivotal U.S. Testing to Start This Summer.”
Subscribe to our Newsletter and get the complete health program for a health you.